<DOC>
	<DOCNO>NCT02192567</DOCNO>
	<brief_summary>This open-label , sequential dose escalation expansion study evaluate safety , pharmacokinetics DS-5573a Japanese patient advance solid malignant tumor .</brief_summary>
	<brief_title>Open Label Study DS-5573a</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Advanced solid tumor refractory standard treatment , standard treatment available . Eastern Cooperative Oncology Group performance status ( PS ) 0 1 Have follow concomitant disease history follow disease within 6 month enrollment : Cardiac failure ( NYHA â‰¥ ClassIII ) , myocardial infarction , cerebral infarction , unstable angina , arrhythmia require treatment , coronaryartery/peripheral artery bypass surgery , cerebrovascular disease , pulmonary thromboembolism , uncontrolled deepvein thrombosis clinically severe thromboembolic event , autoimmune disorder require treatment . Severe uncontrolled concomitant disease . Clinically active brain metastasis define symptomatic requiring treatment .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced solid malignant tumor</keyword>
	<keyword>phase 1</keyword>
	<keyword>oncology</keyword>
</DOC>